SCHEMBL4055876

SCHEMBL4055876

Fc1ccccc1-c1ccc2nc(-c3cccc(OCC4CC4)c3)oc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VSIR Q9H7M9 2/20 0.54
GPR119 Q8TDV5 9/20 0.53
ACACA Q13085 6/20 0.48
ACACB O00763 5/20 0.46
ACHE P22303 1/20 0.44
F2RL3 Q96RI0 1/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
CASP3 P42574 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
SENP8 Q96LD8 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4055472 0.90 GPR119 (0.52) VSIRGPR119ACACAACACBACHE
SCHEMBL4060803 0.85 SMN1; SMN2 (0.57) VSIRGPR119KDM4EALDH1A1TP53
SCHEMBL13620568 0.84 VSIR (0.56) VSIRGPR119KDM4EALDH1A1TP53
SCHEMBL4054615 0.84 VSIR (0.61) VSIRGPR119F2RL3
SCHEMBL4053509 0.83 VSIR (0.55) VSIRGPR119KDM4EALDH1A1TP53
SCHEMBL4061897 0.83 VSIR (0.52) VSIRGPR119F2RL3CASP3RAB9A
SCHEMBL4051457 0.82 VSIR (0.56) VSIRGPR119KDM4EALDH1A1MAPT
SCHEMBL4057255 0.82 VSIR (0.58) VSIRGPR119KDM4EALDH1A1TP53
SCHEMBL4060165 0.82 VSIR (0.58) VSIRGPR119KDM4EALDH1A1TP53
SCHEMBL4057690 0.82 GPR119 (0.55) VSIRGPR119ACACAACACBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B VSIR 4618/4885GPR119 1677/4885ACACA 3208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.